Madrigal Pharmaceuticals, Inc.
NASDAQMDGL heads into its June 17 earnings date with short sellers in modest retreat and a cost-to-borrow that just doubled in a single session, creating a quietly charged setup for a stock that has barely moved in a month. The most notable shift in short positioning is the direction of travel. Short interest as a percentage of free float has fallen from a local peak around 31.6% in…
Snapshot as of 22 Jun 2026
MDGL heads into its June 17 earnings date with short sellers in modest retreat and a cost-to-borrow that just doubled in a single session, creating a quietly charged setup for a stock that has barely moved in a…
Madrigal Pharmaceuticals heads into the post-earnings stretch with short sellers retreating and the Street turning incrementally more constructive — the tension being that even after a 6.4% earnings-day pop, shorts…
Madrigal Pharmaceuticals posted Q1 2026 results today that landed above expectations on both lines — yet the stock fell 3% on the session to close at $502.47, and is down nearly 9% over the past month. The disconnect…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MDGL — free to start on ORTEX.
Sign up for free →Open MDGL on ORTEX